Mubadala Capital

Activity in this selectionOct 4, 2026 · Biotech · Jan 1, 2026

By stage

Series B2

Series C+1

Biotech3

United States3

3 in this selection

Jun 24

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B

Role not disclosed

Apr 15

Provides AI-powered platforms and integrated services for drug discovery and development

$40MSeries E

Role not disclosed

Jan 12

Develops regenerative biologics to restore tissue function

$33.5MSeries B

Role not disclosed